TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details Narrative) - USD ($)		2 Months Ended	12 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Jan. 11, 2018	Mar. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Proceeds from exercise of warrants			$ 981,948
Subsequent Event [Member]
Common stock issued for conversion	11,700,002
Subsequent Event [Member] \| Warrants [Member]
Proceeds from exercise of warrants		$ 5,717,345
Number of warrants exercised		30,492,070
Subsequent Event [Member] \| Series B Convertible Preferred Stock [Member]
Conversion of preferred stock, shares	1,755